Anemia Drug Omontys Recalled

Omontys | Anemia | Peginesatide | The Maher Law Firm | Frank EidsonAffymax and Takeda, the manufacturers of Omontys (Peginesatide) are issuing a voluntary recall of the drug due to life threatening and fatal events reported in patients receiving Omontys.

This voluntary recall is being conducted with the knowledge of the FDA (Food and Drug Administration), who approved the drug in March of 2012.

In a statement, Anne-Marie Duliege, M.D., M.S., Chief Medical Officer, Affymax, Inc. said,  ”This recall has been initiated due to postmarketing reports of serious hypersensitivity reactions in patients who received OMONTYS.  Use of OMONTYS may result in serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal.  The rate of overall severe hypersensitivity reactions reported is approximately 0.2%, with approximately a third of these being serious in nature including anaphylaxis requiring prompt medical intervention and in some cases hospitalization.”

Omontys (Peginesatide) is an injection used for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.   All lots of Omontys are affected by this recall.

At, our dangerous drug lawyers are investigating claims involving Omontys (Peginesatide). Well-versed in the product liability laws that protect consumers, our attorneys can help you obtain fair compensation for your suffering.  Contact an experienced  RxRecall Lawyer today. Call 1-888-884-1507 to schedule a free consultation.

Bookmark and Share

Comments are closed.